Cancer has remained one of the biggest challenges for the medical industry in the past 40 years, with no definitive cure to date. Though cancer in its earlier stages is often treatable, the fear of remission remains. Aside from affecting the quality of life, cancer treatments are immensely expensive. According to Zion Market research, the cost of cancer care has increased by 27% in the last decade.
The pandemic is leading to even more stress and poor lifestyle choice. Down the road, it could lead to a spike in cancer cases. The direct medical cost of cancer is estimated to be approximately $58 billion in 2020 and will rise at double-digit rates over the next decade according to the National Institutes of Health. However, many pharmaceutical companies have reported progress in developing effective treatments for various types of cancer.
Companies such as TG Therapeutics, Inc. (TGTX – Rated “B” – Buy), Mesoblast Ltd. (MESO), and Trillium Therapeutics, Inc. (TRIL – Rated “A” – Strong Buy) have reported substantial progress in developing effective treatments. These drugs are awaiting approval, but their stocks have soared substantially year-to-date and could gain further.
TG Therapeutics, Inc. (TGTX)
TGTX is a biopharmaceutical company engaged in the research, development, and commercialization of cancer treatment drugs and autoimmune disease medication. TGTX has gained more than 125% year-to-date. The stock hit its 52-week high of $27.62 on September 2nd.
In the past couple of weeks, TGTX successfully rolled out an effective FDA-approved Umbralisib drug for treating different types of lymphoma. It also made significant progress in the development of drugs catering to leukemia.
The breakthrough advancement in the field of cancer and lymphoma has allowed the company to garner the attention of the global medical industry. TGTX expects to roll out its new drugs for commercial use in the market by the second half of 2020, as well as complete phase three trials and receive FDA approval on two of its drugs currently under development.
How does TGTX stack up for the POWR Ratings?
A for Trade Grade
B for Buy & Hold Grade
A for Peer Grade
B for Overall POWR Rating.
It is also ranked #26 out of 373 stocks in the Biotech industry.
Mesoblast Ltd. (MESO)
MESO develops and supplies regenerative allogeneic cellular medicines. Its proprietary regenerative technology is based on mesenchymal lineage adult stem cells, which targets advanced stages of critical ailments. On September 15th, MESO was awarded the Fierce Biotech Innovation of the Year award for remestemcel-L.
It received ethics approval and…
Continue reading at STOCKNEWS.com